Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Intra-Cellular Therapies logo

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Key Stats

Today's Range
$131.87
$131.87
50-Day Range
$131.87
$131.87
52-Week Range
$70.90
$131.98
Volume
N/A
Average Volume
1.57 million shs
Market Capitalization
$14.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$118.00
Consensus Rating
Hold

Company Overview

Intra-Cellular Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

ITCI MarketRank™: 

Intra-Cellular Therapies scored higher than 16% of companies evaluated by MarketBeat, and ranked 876th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 8 hold ratings, and no sell ratings.

  • Downside Risk

    Intra-Cellular Therapies has a consensus price target of $118.00, representing about 10.5% downside from its current price of $131.87.

  • Amount of Analyst Coverage

    Intra-Cellular Therapies has received no research coverage in the past 90 days.

  • Read more about Intra-Cellular Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ITCI.
  • Dividend Yield

    Intra-Cellular Therapies does not currently pay a dividend.

  • Dividend Growth

    Intra-Cellular Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ITCI.
  • MarketBeat Follows

    1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

  • Percentage Held by Institutions

    92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intra-Cellular Therapies' insider trading history.
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ITCI Stock News Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Intra-Cellular Therapies
See More Headlines

ITCI Stock Analysis - Frequently Asked Questions

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings results on Friday, February, 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The biopharmaceutical company earned $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative trailing twelve-month return on equity of 9.93%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/21/2025
Today
10/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITCI
CIK
1567514
Employees
560
Year Founded
2002

Price Target and Rating

High Price Target
$132.00
Low Price Target
$89.00
Potential Upside/Downside
-10.5%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$139.67 million
Net Margins
-14.07%
Pretax Margin
-13.87%
Return on Equity
-9.93%
Return on Assets
-8.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.66
Quick Ratio
7.51

Sales & Book Value

Annual Sales
$680.50 million
Price / Sales
20.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.15 per share
Price / Book
21.44

Miscellaneous

Outstanding Shares
106,522,000
Free Float
103,563,000
Market Cap
$14.05 billion
Optionable
Optionable
Beta
0.69

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ITCI) was last updated on 10/7/2025 by MarketBeat.com Staff
From Our Partners